The latest from Faes Farma


July 30th, 2026

Faes Farma increases its revenue by 27% and posts a net profit of 57 million in the first half of the year, reaffirming its guidance for 2026


The Group’s total revenue stands at 391.5 million euros (+27%), with the Farma division reaching 340 million euros (+28%), driven by international growth and the consolidation of the ophthalmology business. EBITDA reached […]



More info

July 1st, 2026

Faes Farma advances its international expansion through an agreement to commercialise a new urology treatment in Latin America


The company has signed an exclusive licensing and supply agreement with Dongkook Pharmaceutical to register and commercialize Uresco in 13 Latin American countries. The agreement includes a total amount of up to […]



More info

June 25th, 2026

Faes Farma holds its Annual General Shareholders’ Meeting following a key year in the execution of its Strategic Plan


Shareholders approved all items on the agenda, including the 2025 annual accounts, as well as the appointment of Jacobo Llanza and Ángel Agudo as members of the Board of Directors. The Meeting […]



More info

All the news